Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Zacks Investment Research - ATE upgareded to $28/share

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Dec 07, 2020 6:36pm

237 Views

Post# 32054685

RE:Zacks Investment Research - ATE upgareded to $28/share

Did they put a time frame of years for that $28/share? Just wondering if it will be in my lifetime or if it's like Knight Therapeutics (T.GUD) where the CEO Goodman says "plan on it for your grandkids at the earliest not for yourself." At my age I decided to get out of that one - that was about 3 years ago when it was in the $8 range - now just under $5.50.

I would hope ATE has a more aggressive future but still not sure I might see $28.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market